METAPHYLAXIS OF URATE NEPHROLITHIASIS IN THE NAMANGAN REGION: A CLINICAL EXPERIENCE

DIGITAL OBJECT IDENTIFIER (DOI): https://doi.org/10.67620/sai.59d0002
Mazhikhanov Baxodir1
1 Department of Urology-Endourology, Namangan Regional Multidisciplinary Medical Center, Namangan, Uzbekistan
ReceivedSep 19, 2026
RevisedOct 04, 2026
PublishedOct 09, 2026

Аннотация

Urate nephrolithiasis is an important urological problem in the Namangan region, where climatic and dietary factors may contribute to stone formation and recurrence. This study summarized clinical experience with personalized metaphylaxis for urate nephrolithiasis. A total of 120 patients with urolithiasis who underwent surgical treatment at the Department of Urology-Endourology of the Namangan Regional Multidisciplinary Medical Center during 2024–2025 were evaluated. Spectrometric stone analysis confirmed urate calculi in 60 patients, who formed the metaphylaxis group. These patients underwent metabolic assessment, correction of fluid intake and diet, urine pH monitoring, and citrate alkalizing therapy when indicated. The approach was tailored according to metabolic evaluation, renal function, comorbidities, and individual clinical characteristics. The metaphylaxis protocol included fluid intake of at least 2 L/day, restriction of animal protein, and maintenance of urine pH within 5.2–6.8 using citrate therapy. Febuxostat at 80 mg/day for 1 month was prescribed episodically when urine pH rose above the target range. During 12 months of follow-up, no recurrent stone formation was observed among the 60 patients (0/60). These findings suggest that individualized metaphylaxis combining adequate hydration, dietary modification, and urine pH correction may be effective for short-term prevention of recurrent urate nephrolithiasis in the Namangan region.

Ключевые слова

urate nephrolithiasis, metaphylaxis, urolithiasis, citrate therapy, stone recurrence, Namangan region.

Использованная литература

1. Alghamdi, A., Alqurashi, E. A., Alsubaie, A. T., et al. (2025). Management of recurrent urolithiasis: Advances in preventive strategies. 2. Banov, P., & Ceban, E. (2018). The efficacy of metaphylaxis in treatment of recurrent urolithiasis. 3. Borisov, V. V., & Shilov, E. M. (2016). Litholytic therapy for urate nephrolithiasis (clinical lecture). 4. Chaban, N. G., Putin, A. Yu., Rapoport, L. M., et al. (2017). Phytopreparations in the prevention and treatment of urate nephrolithiasis. 5. Coe, F. L., Evan, A., & Worcester, E. (2005). Kidney stone disease. Journal of Clinical Investigation, 115(10), 2598–2608. 6. Fathi, R. (2022). Optimization of urolithiasis treatment and diagnosis in the Turkestan region. 7. Kaprin, A. D., Apolikhin, O. I., et al. (2022). The incidence of urolithiasis in the Russian Federation from 2005 to 2020. 8. Krasiuk, I. V., Hrydniev, A. A., & Pylypenko, Y. (2025). A modern view on the prevention and metaphylaxis of urolithiasis. 9. Malkhasyan, V., Gazimiev, M. A., Martov, A. G., et al. (2022). Current state of metaphylaxis of urinary stones in Russian Federation. 10. Nakipova, Z., Oshibayeva, A., & Babayeva, G. A. (2026). Epidemiology and risk factors of urolithiasis in the Turkestan region: A case-control study. 11. Otakulov, G., & Yakubov, A. (2026). Causes of urolithiasis and its prevention. 12. Tagayeva, Z. (2025). Modern aspects of the metaphylaxis management for recurrent urolithiasis. 13. Tiselius, H.-G. (2003). Epidemiology and medical management of stone disease. 14. Zisman, A. L. (2017). Effectiveness of treatment modalities on kidney stone recurrence. Clinical Journal of the American Society of Nephrology, 12(10), 1699–1708.

Как цитировать

Mazhikhanov Baxodir (2026). METAPHYLAXIS OF URATE NEPHROLITHIASIS IN THE NAMANGAN REGION: A CLINICAL EXPERIENCE. Science and Innovation, 5(9), 12-17. https://doi.org/10.67620/sai.59d0002